Unexpectedly, Gfra2 plays a significant role in heart development via a noncanonical signaling pathway that is independent of known ligands and the co-receptor RET tyrosine kinase.
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In Brief Ishida et al. show that GPI-anchored neurotrophic factor receptor Gfra2 specifically marks cardiac progenitor cells (CPs) in mouse and human, providing a method for isolating CPs. Unexpectedly, Gfra2 plays a significant role in heart development via a noncanonical signaling pathway that is independent of known ligands and the co-receptor RET tyrosine kinase.
INTRODUCTION
The heart is the first morphologically distinct developing organ in vertebrates. The primordial heart is derived from the anterior part of the lateral plate mesoderm as cardiac progenitors (CPs) being one of the earliest populations emerging from the primitive streak at gastrulation (Kinder et al., 1999; Rana et al., 2013) . Lineage tracing experiments have led to the identification of CPs in the first (FHF) and second heart field (SHF) according to their anatomical origin and destiny (Rana et al., 2013) . Recently, studies have delineated the complex molecular mechanisms underlying cardiomyocyte differentiation (Kathiriya et al., 2015; Paige et al., 2015) ; however, our knowledge of the precise spatiotemporal mechanisms that regulate the segregation, identity, and fate of CPs remains incomplete. A major hurdle is the paucity of reliable and specific markers to identify CPs, especially for the robust isolation of living CPs using cell sorting, circumventing the requirement of genetic modification for tagging CPs. Previous reports have demonstrated that Kinase insert domain receptor (KDR, also known as Flk-1), platelet-derived growth factor receptor alpha (PDGFRA), KIT, C-X-C chemokine receptor type 4 (CXCR4), and/or Prion protein (PrnP) can be used in defined combinations to identify and harvest CPs (Bondue et al., 2011; Hidaka et al., 2010; Kattman et al., 2006 Kattman et al., , 2011 Nelson et al., 2008; Yang et al., 2008) . In vitro clonal-tracing studies have revealed that both KDR + /PDGFRA + and KDR low+ / KIT neg cell populations contain highly enriched multipotent progenitors producing not only cardiomyocytes but also endothelial and smooth muscle cells in mouse and human, respectively (Kattman et al., 2006 (Kattman et al., , 2011 Yang et al., 2008) . Moreover, since the expression pattern of each of these factors in the embryo is dynamic and not specific for the cardiac lineage (Hidaka et al., 2010; Kataoka et al., 1997; McGrath et al., 1999; Yang et al., 2008) , concerns have been raised about the purity of CPs harvested using these markers. More recently, a cellsurface protein, hyperpolarization-activated cyclic nucleotidegated potassium channel 4 (HCN4), has been reported to be transiently specific for FHF CPs during the earliest phase of cardiomyogenesis (Spä ter et al., 2013) . However, because there is no commercially available antibody against the extracellular domain of this molecule, its use in cell-sorting experiments is limited. Thus, identification of a CP-specific surface antigen for which an antibody is readily available is essential for furthering our understanding of the critical early events in heart development.
In this study, we found that Glial cell line-derived neurotrophic factor receptor alpha 2 (Gfra2) specifically marks CPs of the FHF and SHF in mouse and human (Airaksinen and Saarma, 2002; Paratcha and Ledda, 2008) . The specificity and expression pattern of Gfra2 provides a reliable means to isolate stage-specific CPs with high purity. Strikingly, Gfra2 is essential for heart development, whereas Gfra1, another member of the Gfra receptor family, is functionally redundant. Finally, we demonstrate that the pathway by which GFRA1/2 modulates heart development is independent of the classical Gfra receptor family signaling pathway via the RET protooncogene.
RESULTS

Gfra2 Specifically Marks Both FHF and SHF CPs
According to previous single-cell expression profiling of mouse embryonic CPs between days 7.5 and 8.0 post-conception (E7.5-E8.0), we observed that Gfra2, a specific receptor for a neurotrophic factor Neurturin (NRTN), was expressed in CPs but not in embryonic stem cells (ESCs) (42.31 ± 22.53 SEM of CPs versus 0.00 of ESCs in Reads Per Millions, respectively) (Brouilette et al., 2012; Kokkinopoulos et al., 2015) . This was consistent with the data demonstrating that Gfra2 was co-expressed within the cardiac mesoderm expressing Mesp1 (Bondue et al., 2011) . To confirm the expression pattern of Gfra2 in mouse embryos, we conducted wholemount in situ hybridization (WISH) analyses in serial stages of early mouse embryos and found that Gfra2 was detected from the Early Allantoic Bud stage simultaneously with one of the earliest markers of CPs, Isl1, and was clearly expressed in the cardiac crescent from E7.5 to E8.5 (Figures 1A and S1A) (Downs and Davies, 1993; Kokkinopoulos et al., 2015) . Single-cell expression profiling suggests that Isl1 precedes Gfra2, because Isl1-expressing CPs had a higher incidence of expression of Gfra2 after they had started to express a common marker for the FHF and SHF, Nkx2-5, as they further differentiated ( Figure S1B ) (Kokkinopoulos et al., 2015) . Thereafter, Gfra2 was downregulated in the heart field by the tensomite stage (E8.75) upon formation of the heart tube (Figure 1A) . Immunofluorescence micrographs indicated that GFRA2 protein was prominently detected in the early headfold (EHF) stage CPs ( Figure 1B ) (Downs and Davies, 1993) . Serial sections of the three-somite stage embryos revealed that GFRA2 co-localized with NKX2-5, TBX5, HCN4 (the FHF), and ISL1 (the SHF) (Figures 1C and S1C) (Cai et al., 2003; Devine et al., 2014; Kokkinopoulos et al., 2015; Liang et al., 2013; Spä ter et al., 2013; Stanley et al., 2002) . Therefore, GFRA2 can be considered a marker of CPs within both the FHF and SHF in mouse embryos.
GFRA2 Predominantly Identifies CPs Derived from Pluripotent Stem Cells
Next, to clarify whether GFRA2 marks CPs derived from pluripotent stem cells, we investigated the expression of Gfra2 during cardiac differentiation of mouse ESCs. Quantitative real-time reverse transcription PCR (qPCR) demonstrated that Gfra2 was transiently expressed with its peak at differentiation day 7, before the initiation of spontaneous beating of differentiated cardiomyocytes (Figure 2A ). Flow cytometry using an antibody raised against the extracellular domain of GFRA2 revealed that GFRA2 could be identified between differentiation days 4-9, among the PDGFRA positive mesodermal cells (Figures 2B and S2A (Cai et al., 2003; Devine et al., 2014; Kokkinopoulos et al., 2015; Liang et al., 2013; Spä ter et al., 2013; Stanley et al., 2002) . These data were consistent with our histological results in mouse embryos ( Figures 1C and S1C ).
To further characterize GFRA2 + cells during cardiac differentiation, we investigated the relationship between GFRA2-expressing CPs and the well-validated earliest CPs of the KDR + / PDGFRA + population in differentiating mouse ESCs (Kattman et al., 2006 (Kattman et al., , 2011 . KDR and PDGFRA were already expressed by day 3 of differentiation as previously described (Kattman et al., 2011) , and KDR expression was downregulated in the PDGFRA + population at day 6 ( Figure 3A ). Of note, from day 4 to 5, almost the entire KDR + /PDGFRA + population expressed GFRA2. Thus, GFRA2 could also mark the earliest mouse CPs in cardiac differentiating ESCs. When we isolated a GFRA2 + / KDR + /PDGFRA + triple-positive population on day 4 and cultured the cells for a further 7 days, they gave rise not only to cardiomyocytes, but also to endothelial cells ( Figure 3B ). Given that GFRA2 marked KDR + /PDGFRA + CPs on differentiation day 4, the earliest GFRA2 + CPs would be expected to be multipotent based on previous reports (Bondue et al., 2011; Kattman et al., 2011 (arrows) . Once the heart tube is formed and the looping initiated, Gfra2 is downregulated (red arrowheads). Gfra2 was also expressed in migrating neural crest cells and the rhombomere 4 (white arrowheads). n = 3. Scale bar, 250 mm. EHF, early headfold; LHF, late headfold.
(B and C) Immunohistochemical (IHC) images of GFRA2 in an EHF and three-somite stage embryo. GFRA2 was expressed in the mesodermal regions corresponding to the heart field. n = 4. Scale bar, 50 mm. FHF, first heart field; SHF, second heart field. See also Figure S1 . (G) Quantitative analyses by Flo for HCN4, NKX2-5, TBX5, and ISL1 in GFRA2 + CPs at day 7. Bar graph represents of the proportion of FHF and SHF as mean ± SEM. n = 3. See also Figure S2 and Movie S1.
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ESCs or induced pluripotent stem cells (iPSCs) (Burridge et al., 2011) . Consistent with our results for the mouse, qPCR analyses showed human GFRA2 was induced with a peak just before the appearance of spontaneously beating cardiomyocytes at day 8 of differentiation, both in ESCs and iPSCs (Figures 4A and S3A Figure 4F ) (Yang et al., 2008 Figure 4G ). This is consistent with the data from mouse ESCs and previous work (Kattman et al., 2006 (Kattman et al., , 2011 Yang et al., 2008 (Cong et al., 2013; Wang et al., 2013) . After 10 days of cardiac differentiation, two independent lines of Gfra2-KO ESCs did not show significant defects in cardiomyocyte differentiation, although a minor decrease in the number of differentiated cardiomyocytes was observed without statistical significance . This is consistent with the phenotype of KO mice that showed no cardiac defects (Airaksinen and Saarma, 2002; Hiltunen et al., 2000; Paratcha and Ledda, 2008; Rossi et al., 1999 Rossi et al., , 2003 . Since GFRA1, another member of GFRA-family receptor whose specific ligand is glial cell line-derived neurotrophic factor (GDNF), might be functionally redundant, we generated compound mutant of Gfra1/2 double-KO (DKO) ESCs (Airaksinen and Saarma, 2002; Baloh et al., 2000) . Whereas Gfra1 KO lines exhibited no significant defect in cardiomyocyte differentiation (Enomoto et al., 1998) , the simultaneous ablation of Gfra1 in addition to Gfra2 significantly suppressed cardiomyocyte differentiation (Figures 5A-5C and S4A-S4E). It is unlikely that an off-target mutation is responsible for this phenotype, because two independent single guidance (sg) RNA targeting different portions of the gene resulted in an indistinguishable phenotype ( Figures S4C and S4D ) (Enomoto et al., 1998; Fu et al., 2013; Hiltunen et al., 2000; Rossi et al., 1999 Rossi et al., , 2003 . Thus, Gfra1/2 are required for cardiomyocyte differentiation in vitro, and Gfra1 is functionally redundant for Gfra2. Interestingly, we found that Gfra1 expression was significantly increased in Gfra2 KO ESCs ( Figure 5D ). By contrast, Gfra2 expression was unchanged in Gfra1 KO ESCs. This result suggests that the loss of Gfra2 can be compensated for by upregulated Gfra1, whereas Gfra1 appears to be dispensable for cardiac differentiation (Baloh et al., 2000; Paratcha and Ledda, 2008; Scott and Ibanez, 2001 ). This suggestion is supported by the fact that Gfra1 is not expressed in the heart field in vivo ( Figure S5A ). The canonical signaling cascade acting via GFRA2 depends on a single-pass transmembrane protein, RET tyrosine kinase (Airaksinen and Saarma, 2002) . When the specific ligand, neurturin (NRTN) binds GFRA2, the RET tyrosine kinase is activated by GFRA2/NRTN, to elicit a biological response. To confirm Figure S3 and Movie S2.
whether the GFRA2 signaling pathway affecting cardiomyocyte differentiation depends on RET, we generated Ret KO ESCs lines. As expected from the phenotypes of KO mice, targeting of Ret did not resulted in significantly impaired cardiomyocyte differentiation (Figures 5A-5C, S4A, and S4B) (Airaksinen and Saarma, 2002; Baloh et al., 2000; Paratcha and Ledda, 2008; Schuchardt et al., 1994 ). This observation is also supported by the fact that RET was not expressed in the heart fields (Figure S5A) . In addition, the KO lines of Nrtn, Gdnf, and Nrtn/Gdnf also did not show a significant defect (Figures 5E-5G, S5B, and S5C) (Golden et al., 1999; Heuckeroth et al., 1999; Sá nchez et al., 1996) . Collectively, these results indicate that cardiac differentiation signaling via GFRA2 is independent of the co-receptor RET tyrosine kinase. Previous studies have reported that the direct interaction between Neural Cell Adhesion Molecule (NCAM1) and GFRA1 mediates an alternative GFRA1 signaling pathway via FAK/FYN operating in the absence of any secreted ligands and RET (Paratcha and Ledda, 2008; Paratcha et al., 2003; Sjö strand et al., 2007) . Although NCAM1 was not expressed in the heart field ( Figure S5A ), we cannot exclude the possibility that another cell adhesion molecule mediates a similar signal pathway. To confirm whether a similar pathway is responsible for the cardiac signaling of GFRA2, we investigated the phosphorylation of FAK, FYN, and its downstream ERK1/2 in Gfra1/2 DKO ESCs during cardiomyocyte differentiation ( Figure S6 ). Western blot analyses demonstrated that FAK phosphorylation was slightly but significantly elevated in Gfra1/2 DKO ESCs, whereas FYN and ERK1/2 phosphorylation were unaffected ( Figure S6A ). Since the NCAM1/GFRA1 signal pathway first activates FYN and phosphorylated-FYN activates FAK (Paratcha et al., 2003) , it is unlikely that a signal similar to the NCAM1/GFRA1 signal mediated by a cell adhesion molecule is operating. Thus, it suggests that FAK phosphorylation in Gfra1/2 DKO ESCs becomes elevated by an unknown mechanism. We further tested whether the attenuation of elevated FAK could rescue the phenotype of Gfra1/2 DKO ESCs, since it has been previously reported that activated FAK signaling impaired cardiomyocyte differentiation (Hakuno et al., 2005) . We administered the FAK inhibitor PF-573228 to Gfra1/2 DKO ESCs during their differentiation. However, the efficiency of cardiomyocyte differentiation showed no improvement even though FAK phosphorylation was kept within physiological levels ( Figures S6B and S6C) . Therefore, the upregulation of FAK signaling was not primarily responsible for the defect of Gfra1/2 DKO ESCs. This signaling pathway operating via GFRA2 during cardiomyogenesis must activate effectors of an alternative and critical circuit for cardiomyocyte differentiation.
Gfra1/2 Are Required for Ventricular Compaction In Vivo
To exclude the possibility that the phenotype observed in Gfra1/2 DKO ESCs is an in vitro phenomenon, we generated Gfra1/2 DKO mouse embryos by the direct transduction of (sgRNAs) for Gfra1/ 2 and Cas9 mRNA into zygotes ( Figures 6A-6C and S7A-S7D) (Wang et al., 2013) . At first, we assayed the embryos at E8.5 A B C Figure 6 . Gfra1/2 Play Important Roles for the Heart Development In Vivo (A) Genotype of the Gfra1/2 DKO mouse embryos generated by the direct injection of Gfra1-targeted sgRNA, Gfra2-targeted sgRNA, and Cas9 mRNA into zygotes. (B) WISH analyses of differentiated cardiomyocyte marker Nppa in Gfra1/2 DKO and WT littermate embryos at E8.5. Nppa expressions disappeared in DKO embryos (red arrows). Scale bar, 250 mm. (C) H&E staining for the hearts of Gfra1/2 DKO E17.5 embryos. The compaction layers of myocytes were thin, and the alignments of cardiomyocytes were impaired in Gfra1/2 DKO embryos as compared to the control hearts (mCherry sgRNA and Cas9 mRNA transduced embryos) and Gfra1/2 compound heterozygote mutant. Gfra1 null resulted in kidney agenesis as previously described (black arrowheads, No), whereas the well-developed kidney was observed in the heterozygotes and WT (black arrows, +) (Enomoto et al., 1998) . The mutation of each embryo induced by CRISPR/Cas9 is shown in Figure S7B . IVS, intraventricular septum; RV, right ventricle; LV, left ventricle. Scale bar, 500 mm in whole-heart images and 100 mm in higher magnification. See also Figure S7 . just after heart tube formation, since embryonic defects or lethality would preclude the analysis of later stage embryos. Embryos containing multiples of three base insertions/deletions inside the exon were discarded from the analysis because the presence of functional protein production could not be refuted ( Figure 6A ). We examined cardiomyocyte differentiation of Gfra1/2 DKO embryos by WISH using a marker of differentiated cardiomyocytes, Nppa (also known as ANF) (Bruneau et al., 2001; Christoffels et al., 2000) . As expected from our ESC experiments, Gfra1/2 DKO embryos exhibited a significant reduction of Nppa (Figure 6B ), suggesting the cardiomyocyte differentiation process was significantly affected. As expected from the data of Gfra2 KO ESCs ( Figure 5D ), Gfra2 single-KO embryos showed significant but transiently elevated Gfra1 expression by E8.5 in the heart field ( Figure S7A ). However, despite the fact that cardiomyocyte differentiation was impaired, the macro-and micro-anatomical morphology of the formed heart tube appeared unaffected in any DKO embryos (Figures 6B and S7B) . This suggests that the reduction of Nppa in Gfra1/2 DKO embryos simply reflected a delay of cardiomyocyte differentiation. To clarify this, we analyzed the Gfra1/2 DKO embryos at E17.5 ( Figures 6C,  S7C, and S7D) . Surprisingly, DKO embryos had the capacity to develop up to this stage without edema, and developed hearts were also observed ( Figure 6C ). This indicates that sufficient cardiomyocyte differentiation occurred in DKO embryos to support the fetal circulation. Further histological examination unexpectedly revealed that Gfra1/2 DKO hearts at E17.5 suffered from noncompaction cardiomyopathy ( Figures 6C and S7D ). Excessively prominent trabeculations and deep intra-trabecular recesses, which are characteristic features of noncompaction cardiomyopathy, were apparent, but no other congenital heart disease in DKO embryos was observed. However, the structure of sarcomeres and mitochondria were not altered ( Figures 7A  and S7C ), suggesting that noncompaction was not caused by the abnormality of sarcomeres and mitochondria (Towbin et al., 2015) . The absence of Gfra1/2 and Nrtn at the sites of trabeculation and compaction suggests that RET-dependent and -independent GFRA1/2 signal pathways do not directly or locally regulate trabeculation and compaction ( Figures S7A, S7E, and S7F) . Importantly, we found that NOTCH1 in total protein and its downstream molecules BMP10 and ERBB4 were missing in DKO hearts at E9.5 ( Figure 7B ). NOTCH signaling is essential for proliferation and differentiation of ventricular cardiomyocytes through which proper trabeculated and compacted myocardial layers are formed, and mutants with NOTCH signaling defects exhibit a noncompaction phenotype (de la Pompa and Epstein, 2012; Grego-Bessa et al., 2007; Luxá n et al., 2013; Zhang et al., 2013) . Thus, the ventricular noncompaction observed in DKO embryos likely resulted from altered NOTCH signaling ( Figures  7B and 7C) .
Taken together, these results suggest that GFRA1/2 plays an important function in normal mammalian heart development, especially for ventricular wall compaction, but an unknown mechanism could compensate for cardiomyocyte differentiation due to the lack of GFRA1/2 in vivo. Thus, taken together, our data reveal a non-canonical signal cascade via GFRA1/2 is indispensable for heart development in vivo.
DISCUSSION
Here, we report a surface marker, GFRA2, that is specific for CPs in mouse and human. We show that the expression of (Bondue et al., 2011; Kattman et al., 2006 Kattman et al., , 2011 Yang et al., 2008) . However, it remains an open question as to whether all of these cells or only a proportion of these cells are CPs. In this study, we found that almost all mouse KDR low+ /PDGFRA + express GFRA2 (Figure 3) . However, the situation is likely somewhat different in human. The proportion of hGFRA2-expressing cells among hKDR low+ /hPDGFRA + population is much lower ( Figure 4F ). As expected, hKDR low+ /hPDGFRA + cells are negative for KIT (Yang et al., 2008) . Of note, most GFRA2-negative hKDR low+ /hPDGFRA + cells failed to differentiate to cardiac cells ( Figure S3E ), which strongly supports the specificity of hGFRA2 for human CPs. Thus, in humans, the additional usage of hGFRA2 labeling is superior to the previously proposed protocols to isolate multipotent CPs with high purity. Furthermore, the use of GFRA2 labeling in addition to KDR and PDGFRA will enrich for more mature unipotent CPs which cannot be isolated with previous protocols dependent on KDR expression. It is interesting that these unipotent late-stage GFRA2 + CPs represent not only the FHF, represented by HCN4/TBX5 and already known as unipotent, but also the SHF identified through expression of ISL1, because the SHF CPs are generally thought as multipotent ( Figures 2G, 4E , S2D, and S2E) (Devine et al., 2014; Evans et al., 2010; Kelly and Evans, 2010; Kokkinopoulos et al., 2015; Lescroart et al., 2014; Spä ter et al., 2013) . This evidence indicates that the late-stage expression of GFRA2 excludes the multipotent SHF but includes the already committed but not fully differentiated SHF lineage. Thus, here we propose a strategy to isolate stage-specific human and mouse CPs with GFRA2, PDGFRA, and KDR (Figure 7D We found that Gfra1/2 DKO mouse ESCs showed a severe impairment of cardiomyocyte differentiation. Our data reveal that GFRA2 plays a pivotal role in cardiomyocyte differentiation in vitro that can be compensated by upregulation of GFRA1. Examples of an ectopic upregulation of an evolutionally duplicated paralogous gene to compensate for loss of a gene have been described (Barbaric et al., 2007 ). An evolutionally close relationship between Gfra1 and Gfra2 suggests that a preserved common enhancer drives Gfra1 if Gfra2 is not expressed in CPs, whereas a high level of Gfra2 primarily suppresses Gfra1 (Barbaric et al., 2007; Hä tinen et al., 2007) . However, the phenotype of KO of the known ligands for GFRA1 and 2, Gdnf and Nrtn, or KO of its co-receptor Ret did not show any defect of cardiomyocyte differentiation (Figures 5, S4, and S5) . Interestingly, we observed a tendency of a slightly reduced yield of cardiomyocytes in single KO of Gfra1, Gfra2, and Ret, although not to a statistically significant degree ( Figure 5B ). Given the evidence that previously reported KO mice of each gene also did not show any heart defect (Enomoto et al., 1998; Heuckeroth et al., 1999; Rossi et al., 1999; Sá nchez et al., 1996) , the role of classic RET-dependent GFRA1/2 signals are unlikely to be vital for heart development. In addition, whereas an alternative GFRA1 signal pathway via NCAM1/FYN/FAK is known (Paratcha et al., 2003; Sjö strand et al., 2007) , our data showed that NCAM1, FYN, and FAK were not involved in the cardiac differentiation defect in the Gfra1/2 DKO ( Figure S6 ). Thus, the pathway by which GFRA2 modulates heart development is likely to be distinct from previously established pathways. To uncover the nature of this alternative non-canonical signaling pathway acting via GFRA1/2, further investigation is required, to identify molecules interacting directly with GFRA2 in the context of cardiac differentiation.
In contrast to the in vitro phenotype, the loss-of-function of Gfra1/2 showed a different phenotype in vivo. In E8.5 DKO embryos, Nppa expression disappeared, which is likely consistent with the impaired in vitro cardiomyocyte differentiation of DKO ESCs. However, viable E17.5 DKO embryos possessing a developed heart were observed, indicating that cardiomyocyte differentiation itself occurred to form a functional fetal heart in vivo. Indeed, although missing Nppa, the heart tube of E8.5 DKO embryos seemed morphologically normal ( Figures 6B and S7B ). This evidence is inconsistent with the in vitro phenotype of ablated cardiomyocyte differentiation in DKO ESCs. Thus, the disappearance of Nppa in E8.5 DKO embryos might simply represent the delay of cardiomyocyte differentiation or anomalous sequential events inside the cardiomyocytes in DKO embryos. We propose that an unknown compensatory mechanism functions in vivo to circumvent the lack of GFRA1/2 to promote cardiomyocyte differentiation. Although the differentiation protocol for ESCs used in this study provides a strong drive toward cardiomyocytes with a defined set of growth factors (Kattman et al., 2011; Wamstad et al., 2012) , these conditions are probably insufficient to perfectly mimic the in vivo environment for cardiomyocyte differentiation.
E17.5 DKO embryos showed noncompaction cardiomyopathy without other congenital heart diseases (Towbin et al., 2015; Zhang et al., 2013) . We speculate that these DKO mice would not survive after birth because of the extremely thin compact layer of the ventricular wall. However, absence of edema in E17.5 DKO embryos suggests that the contractile apparatus in DKO cardiomyocytes at least developed sufficiently to support the fetal circulation. Unfortunately, germline deletion of Gfra1 does not allow neonates to survive due to kidney agenesis (Figure 6C) (Enomoto et al., 1998; Sá nchez et al., 1996) . Thus, to confirm the perinatal prognosis, a conditional knockout will be required.
Importantly, we found that NOTCH1 and its downstream targets, BMP10 and ERBB4, were significantly downregulated in DKO embryos, and that this might be responsible for the noncompaction defect ( Figures 7B and 7C ) (Grego-Bessa et al., 2007; Luxá n et al., 2013; Zhang et al., 2013) . Given the lack of Nppa expression in NOTCH signal mutants (Luxá n et al., 2013) , it is concluded that the altered NOTCH signal in the endocardium promotes the downregulation of Nppa in DKO embryos. Surprisingly, Gfra2 is expressed by CPs, but not at the sites of trabeculation or compaction (Figures 1, S1 , S7E, and S7F). Thus, the defect within the endocardium is cell autonomously induced by the loss of Gfra1/2 in multipotent CPs and is likely primarily required for ventricular noncompaction, although we cannot exclude a possibility that additional defects within the myocardium of DKO embryos may also contribute to this phenotype ( Figure 7C ).
Taken together, an alternative signaling pathway via GFRA1/2 is indispensable for proper heart development, although the mechanism underlying the signaling pathway of cardiac differentiation mediated by GFRA2 has yet to be elucidated. Future work, involving the clarification of the mechanistic details of this signaling pathway should provide deeper insight into cardiomyocyte differentiation, the biology of CPs, normal trabeculation, and compaction of ventricular myocytes.
EXPERIMENTAL PROCEDURES
The details are given in the Supplemental Experimental Procedures.
Animals
All animal procedures in this project were carried out under the project licenses 70/7254 and 80/2452 and 27-028-001 approved by the Home Office according to the Animals (Scientific Procedures) Act 1986 in the UK and Osaka University Animal Ethical Committee in Japan, respectively.
Cell Culture and Differentiation
Cardiomyocyte induction for mouse E14tg2a ESCs (Magin et al., 1992; Smith and Hooper, 1987) was performed according to standard protocols as previously described (Kattman et al., 2011) . Cardiomyocyte induction from human HUES7 ESCs or iPSCs was undertaken as previously described (Burridge et al., 2011) . Human ESCs were used under the license of the UK Steering Committee (reference number; SCSC13-25). Human iPSCs (iPS-HS1M) were originally established by D.M. using human dermal fibroblasts (HDFs) from a healthy donor under informed consent (Health Research Authority approval 13/LO/0224), for a study to be described elsewhere (D.M., T. McKay, L.D., and A.T., unpublished data).
CRISPR/Cas9-Mediated Genome Editing
The CRISPR/Cas9-mediated genome editing for mouse ESCs and embryos was performed as previously described (Hashimoto and Takemoto, 2015; Wang et al., 2013) .
Flow Cytometry/FACS Cells were sorted as previously described using FACS ARIA II or analyzed by LSR Fortessa II or FACSConto II (BD Biosciences) with FACSDiva 7.0 software (Kokkinopoulos et al., 2015) . 
SUPPLEMENTAL INFORMATION
Flow cytometry (7 days after FACS) F Figure S3 . Related to Figure 4 . hGFRA2 + CPs derived from human iPSCs.
(A) qPCR analysis for human GFRA2 during cardiac differentiation of human iPSCs. A transient expression peak of human GFRA2 was observed at day 8, similar to mouse and human ESCs. Bar graph represents biological triplicates with technical duplicates as mean ± s.e.m.. (B) Flow cytometrical analysis of hGFRA2 and hPDGFRA on differentiation day 8 human iPSCs. Similar to mouse and human ESCs, hGFRA2 + /hPDGFRA + CP population could be clearly seen in cardiac differentiating iPSCs. (C, D) FACS-isolated hGFRA2 + /hPDGFRA + CPs from human iPSCs efficiently differentiated into TNNT2 + cardiomyocytes. Scale bar; 100 µm. (E) Flow cytometrical analyses for hTNNT2 (cardiomyocytes), hPECAM1 (endothelial cells), and hACTA2 (smooth muscle cells; also known as !SMA) 7 days after the FACS-isolation of hGFRA2 + /hKDR low+ /hPDGFRA + /hKIT neg and hGFRA2 neg /hKDR low+ /hPDGFRA + / hKIT neg population. Note hGFRA2 negative population almost lost cardiac differentiation ability. Bar graph represents mean ± s.e.m. N=3. (F) Flow cytometry for hGFRA2, hPDGFRA, and hKDR at day 8 of human ESCs. hGFRA2 + / hPDGFRA + CPs (shown as green dots) lost hKDR expression (right column) as compared with day 4 (Fig. 4f) . (A) Transient ectopic Gfra1 expression in Gfra2 knockout embryos. Gfra1 was expressed in the neural crest lineage (black arrowheads), but not in cardiac crescent (red arrowheads in the upper row) of WT embryo. By contrast, Gfra1 was up-regulated in Gfra2-null embryos in the cardiac crescent at E8.25 (red arrowheads in the upper row of the right column) but not at the the heart region of E9.5 embryo (red arrowheads in the lower row). The heart of E9.5 is indicated as the left lateral view. Scale bar, 250 µm. (B) HE staining of the sections of E8.5 Gfra1/2 DKO #81 mouse embryo and WT littermate. The morphological alteration of the heart tube was not noticed in DKO embryos, although Nppa disappeared (Fig. 6B) . Scale bar; 50 µm. (C) Genotype of the E17.5 Gfra1/2 DKO mouse embryos generated by CRISPR/Cas9 mediated direct genome editing. (D) Summary of the E17.5 mutants obtained via direct genome editing with CRISPR/Cas9. All the cases of Gfra1 null showed kidney agenesis (asterisks). Note that only DKO embryos showed noncompaction. (E) WISH for Isl1, Gfra2, and Nrtn on WT mouse embryos at E9.5 when trabeculation of myocardium occurs. Note Gfra2 and Nrtn were not expressed inside the heart, although we could not exclude that they were expressed in a part of SHF at the dorsal mesentery (red arrowheads) represented by Isl1. Gfra2 and Nrtn was detected weakly at the pharyngeal pouch. The signal at otic vesicle is likely artifact (black arrowheads). The embryos are indicated as left lateral view. N=3. V; trigeminal nucleus, VII/VIII; facial/acoustic nucleus, IX/X glossopharyngeal/vagus nucleus, Scale bar; 250 µm. (F) WISH for Actc1 (a cardiomyocyte marker), Gfra2, and Nrtn on WT mouse embryonic hearts at E14.5 when myocardial compaction occurs. Gfra2 was not expressed in the heart at E14.5 but was detected at alveoli in the lung. Nrtn was observed in the atrium and at the ventricular endocardium, but not in the ventricular myocardium layer. N=3. Scale bar; 750 µm.
Genotype
Heart phenotype Number
Gfra1 -/- (Roche) (Cong et al., 2013; Wang et al., 2013) . Puromycin resistant clones were usually isolated 7 days after the initiation of puromycin selection and mutations in each clone were confirmed by Sanger sequencing of PCR products for the genomic region around the target sequences. Among the homozygously mutated clones, deletions/insertions of multiples of 3 bases were discarded because the possibility of in-frame translation of functional proteins could not be excluded. We confirmed the early termination of the translation into proteins by frame-shift mutations and selected at least 2 different clones for each gene. To exclude the possibility that any off-target effects might be responsible for the observed phenotypes, we designed two independent sgRNAs for each target gene. For direct genome editing in mouse embryos, we microinjected or electroporated sgRNAs and Cas9 mRNAs into the fertilized eggs as previously described (Hashimoto and Takemoto, 2015; Wang et al., 2013) . In brief, we harvested the fertilized eggs of F1 (C57BL/6 xCBA/ca) mice, and in vitro synthesized 100 ng/µL of sgRNA and 50 ng/µL of Cas9 mRNA were injected into one-cell stage embryos simultaneously (Wang et al., 2013) . Alternatively, to introduce sgRNA and Cas9 mRNA, electroporation was performed as previously described (Hashimoto and Takemoto, 2015) . One-cell stage F1 (C57BL/6 xC3H) embryos were placed in the 1 mm gap of the electrode (LF510-PT1-5, BEX) filled with 2.5µl of 1200 ng/µl Cas9 mRNA and 200 ng/µl sgRNAs in Opti-MEM I medium (Gibco). The electric condition applied was two sets of three pulses (Voltage, 25 V; duration, 3 msec; interval, 50 msec; polarity change between the sets) generated by CUY EDIT II electroporator (BEX). Embryos were harvested at E8.5 and E17.5 after oviduct transfer of injected embryos. Yolk sac or tail tissues were subjected for the genome preparation to determine the genotype. PCR primers, sequencing primers and sgRNA design are listed in the table below. WT littermates determined by Sanger sequencing were used as controls in E8.5, and mCherry sgRNA plus Cas9 mRNA transduced embryos were used as controls in E17.5. 
Oligonucleotides for CRISPR/Cas9 mediated gene targeting
Gfra1_ES_1 F R CACCGCAGGCTGTCAGATATATTC AAACGAATATATCTGACAGCCTGC Gfra2_ES_1 F R CACCGCCTGTGACCTCCCGCCTCT AAACAGAGGCGGGGAGGTCACAGGC Ret F R CACCGCAGGTGTTCGATGCAGATG AAACCATCTGCATCGAACACCTGC GDNF F R CACCGATGAAGTTATGGGATGTCG AAACCGACATCCCATAACTTCATC Neurturin F R CACCGCGCTGGAAGGCAGCGGCCC AAACGGGCCGCTGCCTTCCAGCGC Gfra2_ES_2 F R CACCGCTCCAGGTACCGCACCCTT AAACAAGGGTGCGGTACCTGGAGC Cas9 mRNA synthesis F R TTAATACGACTCACTATAGGGAGAATGGACTATAAGGACCACGAC GCGAGCTCTAGGAATTCTTAC Gfra1 sgRNA_1 F R TTAATACGACTCACTATAGGCAGGCTGTCAGATATATTC AAAAGCACCGACTCGGTGCC Gfra2 sgRNA_1 F R TTAATACGACTCACTATAGGCCTGTGACCTCCCGCCTCT AAAAGCACCGACTCGGTGCC Gfra1 sgRNA_2 F R TTAATACGACTCACTATAGTCAAGGCCTCCATAGCGCTG AAAAGCACCGACTCGGTGCC Gfra2 sgRNA_2 F R TTAATACGACTCACTATAGTCTTCATGCCCCGCTTGCAG AAAAGCACCGACTCGGTGCC Gfra2 sgRNA_3
Western blot analysis
Cells were harvested with RIPA buffer with protease inhibitors then provided for sonication. After centrifugation at 14,000 rpm for 15 min, the supernatants were mixed with sample buffer (BioRad) with !-mercaptoethanol and boiled at 95 °C for 5 min. Protein concentrations were determined by the Lowry method and 5 µg of the samples were used for blotting. NuPAGE Bis-Tris 4-12% gradient gel (Thermo Scientific) and PVDF membrane (GE Healthcare) were used for electrophoresis and wet transfer. After blocking with 5% skimmed milk/TBS for 60 min, the primary antibodies, anti-GFRA1, anti-GFRA2, anti-RET, anti-GDNF, anti-Neurturin (all were purchased from Abcam), anti-phospho-FAK, anti-FAK, anti-phospho-ERK1/2, anti-ERK1/2 (Cell Signaling Technologies), anti-phospho-Fyn, anti-Fyn (Abcam), anti-TUBA1A ("Tubulin; Abcam) were suspended with Can Get Signal solution 1 (TOYOBO), and membranes were incubated with antibodies at 4 °C overnight. Next day, membranes were incubated for 2 hours at room temperature in 5% skimmed milk containing horseradish peroxidase conjugated secondary antibodies (Thermo Scientific). Blots were visualized using Super Signal West Dura (Thermo Scientific) and scanned with an Alpha Imager HP Imaging System (Alpha Innotech) or ChemiDoc Touch (BioRad).
Culture of clonally FACS-isolated cells
Single cell sorting of human CPs was performed by FACS ARIA II according to manufacturer's instructions. Sorted cells were plated on mitomycin C treated mouse embryonic fibroblasts with 20% FBS/RPMI in 96-well plates. 5 µM of Y-27632 ROCK inhibitor was added overnight after sorting, then cells were cultured for a further 2 weeks with 20% FBS/RPMI for expansion and differentiation.
Reverse transcription and quantitative real-time PCR analysis
The total RNAs were extracted using an RNeasy mini kit (Qiagen) from each stage of differentiating ESCs or FACS-purified cells. 500 ng of total RNA for each specimen was used for reverse transcription using SuperScript ® II (Life Technologies) and oligo dT primers. Quantitative PCR was conducted in total volumes of 10 µL (0.25 µL of cDNA solutions) using a SYBR ® Green PCR kit (Qiagen) and Rotor Gene 6000. PCR cycles were 95 °C for 10 s, 60 °C for 10 s, and 72 °C for 10 s according to the manufacturer's protocol. For conventional RT-PCR analyses, 50 ng of total RNAs were used for reverse transcription with High-Capacity cDNA reverse transcription kit (Thermo), and 0.5 µL of 20 µL cDNA solutions were provided for 35 to 45 cycles PCR with HotStar Taq (Qiagen). Sequences of the primers are provided in the Supplemental Table. Relative expression levels were calculated using the comparative CT method. GAPDH was used as a constitutively expressed internal control. 
Mouse qPCR and RT-PCR primers
Transmission Electron Micrographs
Dissected 1 mm 3 tissue blocks from the hearts of E17.5 embryo were fixed in half Karnovsky fixative (1% of glutaraldehyde/1% of PFA/0.1 M of sodium phosphate, pH 7.3) for 2 h at 4 °C and post-fixed in 2% of osmium tetroxide//0.1 M of sodium phosphate (pH 7.3) for 2h at 4°C. After dehydration with ethanol, the specimens were incubated in propylene oxide, and embedded Quetol 812 (Nisshin EM). Ultra-thin sections were stained with uranyl acetate and lead citrate, and observed with transmission electron microscope (Hitachi, H-7650) at 80#kV.
Statistical Analysis
Quantitative data are presented as means ± SEM (unless indicated otherwise) and were compared by using a Student's t test or one-way ANOVA. P values of <0.05 were considered as statistically significant.
